Figure 2.

Preexposure prophylaxis of rabies by using AAVs expressing RVNA. (A) RVNA levels in serum following the administration of AAV expressing CR57, CR4098, or EGFP. Groups of 6-week-old female BALB/c mice (n=10) were i.m. immunized with a 10¹² vector genome of AAV. The serum was collected from the peripheral blood samples at the indicated time points post-immunization, and the VNA titers were quantified by the FAVN test. (B) At 24weeks post-primary inoculation, the mice (n=12) were i.c. challenged with 50×mouse LD₅₀ CVS-24 and were then observed daily for 3weeks. The number of survivors in each group was recorded. ^****p < 0.0001.